ACADIA PHARMACEUTICALS INC

ACADIA Pharmaceuticals is a biopharmaceutical company headquartered in San Diego, California, focused on developing and commercializing therapies for central nervous system disorders and rare genetic diseases. The company's commercial portfolio includes NUPLAZID (pimavanserin), approved for hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE (trofinetide), a synthetic analog used to treat Rett syndrome. Both products represent the company's primary revenue streams in the U.S. market.

The company maintains a pipeline of development-stage candidates addressing multiple CNS indications. Pimavanserin is in Phase III trials for negative symptoms of schizophrenia, while ACP-101 has completed Phase III testing for hyperphagia in Prader-Willi syndrome. Additional candidates in earlier stages target Alzheimer's disease psychosis, Lewy body dementia psychosis, essential tremor, treatment-resistant depression, and other rare neurodevelopmental conditions. ACADIA also holds licensing agreements with Neuren Pharmaceuticals and Stoke Therapeutics to expand its pipeline in Rett syndrome and RNA-based CNS medicines.

The company operates with approximately 796 full-time employees and maintains operations primarily in the United States, where its approved products are commercialized and its development programs are conducted.